Managing Skin Effects
Because Daytrana is a patch that is applied to the skin, your patient, or their parent may notice mild skin redness (slight pink to red) or itching.
Below are recommendations and tips that can help maintain healthy skin, and may help prevent skin irritation that your patient may be experiencing.
Recommendations from a panel of expert dermatologists:13
Mild to moderate erythema is a common skin reaction seen with Daytrana. It is not generally a reason to discontinue if seen in isolation.13
To help prevent skin reactions from Daytrana 14,15
- Educate families about alternating patch application sites
- Avoid irritants
- Engage in good skin care practices
Typical levels of redness irritant contact dermatitis (ICD) from transdermal systems
These photographs depict examples of ICD with patch use; may not be
representative of individual results with Daytrana.
To treat ICD from Daytrana13
- Emollients may suffice for temporary relief of irritant reactions at previous patch sites.
- Creams and ointments should not be applied immediately prior to patch application.
- If signs or symptoms of ICD are bothersome and unresponsive to emollients, the following may be considered:
- Application of low (1.0% to 2.5% hydrocortisone ointment) to low-medium (desonide 0.05% or alclometasone 0.05% ointment) potency topical corticosteroid in addition to emollients.
- Avoid continuous corticosteroid application at the same site without resolution for more than 3 weeks.
- Potential adverse events with topical corticosteroid use during treatment with Daytrana are unknown.
If symptoms suggestive of an allergic reaction develop (eg, redness accompanied by edema, papules), Daytrana treatment should be discontinued.
Important Safety Information
Daytrana should not be used in patients with allergy to methylphenidate or patch components; marked anxiety, tension and agitation; glaucoma; tics, diagnosis or a family history of Tourette's syndrome; seizures; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).
Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.
New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Growth and hematologic monitoring is advised during prolonged treatment. Patients should avoid applying external heat to the Daytrana patch. Erythema has been commonly reported. Contact sensitization may occur.
Daytrana should be given cautiously to patients with a history of drug dependence and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder.
Common adverse events reported by patients who received Daytrana in clinical trials were decreased appetite, insomnia, nausea, vomiting, decreased weight, tics, affect lability, and anorexia, consistent with adverse events commonly associated with the use of methylphenidate.
©2008 Shire US Inc., Wayne, PA 19087-5367, (800) 828-2088. All rights reserved.
Daytrana® is a registered trademark of Shire Pharmaceuticals Ireland Limited.
DAY-00032 08/08
This site is strictly intended for U.S. residents and is governed solely by U.S. laws and governmental regulations. Please see our online privacy policy for more information.
While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.
